Evidence map›Paper›PMID 40148827›Full record

ArticleBMC cancer2025

Analysis of extracellular vesicles of frequently used colorectal cancer cell lines.

Marie Boudná, Nicolas Blavet, Tetiana Samoilenko, Táňa Macháčková, Robin Jugas, Petra Vychytilová-Faltejsková, Miroslav Boudný, Renata Bartošová, Jan Kotouček, Vojtěch Bystrý and 3 more

Abstract read
In one paragraph

Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Marie BoudnáCentre for Molecular Medicine, Central European Institute of Technology, Masaryk University, Kamenice 5, Brno, 625 00, Czech Republic.
Nicolas BlavetCentre for Molecular Medicine, Central European Institute of Technology, Masaryk University, Kamenice 5, Brno, 625 00, Czech Republic.
Tetiana SamoilenkoCentre for Molecular Medicine, Central European Institute of Technology, Masaryk University, Kamenice 5, Brno, 625 00, Czech Republic.
Táňa MacháčkováCentre for Molecular Medicine, Central European Institute of Technology, Masaryk University, Kamenice 5, Brno, 625 00, Czech Republic.
Robin JugasCentre for Molecular Medicine, Central European Institute of Technology, Masaryk University, Kamenice 5, Brno, 625 00, Czech Republic.
Petra Vychytilová-FaltejskováCentre for Molecular Medicine, Central European Institute of Technology, Masaryk University, Kamenice 5, Brno, 625 00, Czech Republic.
Miroslav BoudnýCentre for Molecular Medicine, Central European Institute of Technology, Masaryk University, Kamenice 5, Brno, 625 00, Czech Republic.
Renata BartošováCentre for Molecular Medicine, Central European Institute of Technology, Masaryk University, Kamenice 5, Brno, 625 00, Czech Republic.
Jan KotoučekDepartment of Pharmacology and Toxicology, Veterinary Research Institute, Brno, Czech Republic.
Vojtěch BystrýCentre for Molecular Medicine, Central European Institute of Technology, Masaryk University, Kamenice 5, Brno, 625 00, Czech Republic.
Kateřina KoželkováCentre for Molecular Medicine, Central European Institute of Technology, Masaryk University, Kamenice 5, Brno, 625 00, Czech Republic.
Ondřej SlabýCentre for Molecular Medicine, Central European Institute of Technology, Masaryk University, Kamenice 5, Brno, 625 00, Czech Republic. oslaby@med.muni.cz.
Kamila SoučkováCentre for Molecular Medicine, Central European Institute of Technology, Masaryk University, Kamenice 5, Brno, 625 00, Czech Republic. kamila.souckova@ceitec.muni.cz.

Funding

Grantová Agentura České Republiky 20-18889SNational Institute for Cancer Research (Program EXCELES)-Funded by the European Union-Next Generation EU LX22NPO5102
6 · The paper itself

Abstract

Colorectal cancer (CRC) ranks as the second most prevalent malignancy globally, highlighting the urgent need for more effective diagnostic and therapeutic strategies, as well as a deeper understanding of its molecular basis. Extensive research has demonstrated that cells actively secrete extracellular vesicles (EVs) to mediate intercellular communication at both proximal and distal sites. In this study, we conducted a comprehensive analysis of the RNA content of small extracellular vesicles (sEVs) secreted into the culture media of five frequently utilised CRC cell lines (RKO, HCT116, HCT15, HT29, and DLD1). RNA sequencing data revealed significant insights into the RNA profiles of these sEVs, identifying nine protein-coding genes and fourteen long non-coding RNA (lncRNA) genes that consistently ranked among the top 30 most abundant across all cell lines. Notably, the genes found in sEVs were highly similar among the cell lines, indicating a conserved molecular signature. Several of these genes have been previously documented in the context of cancer biology, while others represent novel discoveries. These findings provide valuable insights into the molecular cargo of sEVs in CRC, potentially unveiling novel biomarkers and therapeutic targets.

Indexed as

Colorectal NeoplasmsExtracellular VesiclesBiomarkers, TumorCell Line, TumorGene Expression ProfilingGene Expression Regulation, NeoplasticHCT116 CellsHumansRNA, Long NoncodingBiomarkers, TumorRNA, Long NoncodingCell lineColorectal cancerCRCEVEV cargoEV contentExosomesExtracellular vesicles

Identifiers

PMID40148827
PMCPMC11951637

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.